Fate Therapeutics Inc - Understand $fate stock

$FATE Market Cap: $291.6 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$13.45M

TTM

Gross Margin

Net Earnings

-$178.2M

TTM

Current Assets

$310.3M

Q3 2024

Current Liabilities

$37.42M

Q3 2024

Current Ratio

829.18%

Q3 2024

Total Assets

$495.0M

Q3 2024

Total Liabilities

$132.6M

Q3 2024

Book Value

$362.3M

Q3 2024

Cash

$37.91M

Q3 2024

P/E

-1.636

Nov 29, 2024 EST

Free Cash Flow

-$132.5M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$63.53M	$96.30M	$55.85M	$31.43M	$10.68M	$4.740M	$4.106M	$4.402M	$2.431M	$0.00	$971.0K	$2.670M	$1.170M
YoY Change	-34.03%	72.44%	77.66%	194.33%	125.32%	15.44%	-6.72%	81.08%		-100.0%	-63.63%	128.21%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$63.53M	$96.30M	$55.85M	$31.43M	$10.68M	$4.740M	$4.106M	$4.402M	$2.431M	$0.00	$971.0K	$2.670M	$1.170M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$81.45M	$84.23M	$57.32M	$33.90M	$23.64M	$15.81M	$11.87M	$9.910M	$10.35M	$8.470M	$6.640M	$4.230M	$4.510M
YoY Change	-3.31%	46.95%	69.09%	43.4%	49.53%	33.19%	19.78%	-4.25%	22.2%	27.56%	56.97%	-6.21%
% of Gross Profit
Research & Development	$172.6M	$320.5M	$215.5M	$125.6M	$87.77M	$56.02M	$34.36M	$26.45M	$19.86M	$16.44M	$12.01M	$12.00M	$9.858M
YoY Change	-46.14%	48.69%	71.56%	43.13%	56.67%	63.06%	29.89%	33.19%	20.81%	36.92%	0.07%	21.72%
% of Gross Profit
Depreciation & Amortization	$18.30M	$13.80M	$5.900M	$3.100M	$2.200M	$1.200M	$971.0K	$881.0K	$687.0K	$496.0K	$571.0K	$590.0K	$672.0K
YoY Change	32.61%	133.9%	90.32%	40.91%	83.33%	23.58%	10.22%	28.24%	38.51%	-13.13%	-3.22%	-12.2%
% of Gross Profit
Operating Expenses	$254.0M	$404.7M	$272.8M	$159.5M	$111.4M	$71.83M	$34.36M	$26.45M	$30.21M	$24.90M	$18.65M	$16.23M	$14.46M
YoY Change	-37.22%	48.32%	71.04%	43.19%	55.09%	109.07%	29.89%	-12.45%	21.32%	33.56%	14.91%	12.2%
Operating Profit	-$190.5M	-$308.4M	-$217.0M	-$128.1M	-$100.7M	-$67.09M	-$42.13M		-$27.78M	-$24.90M	-$17.68M	-$13.56M	-$13.29M
YoY Change	-38.22%	42.12%	69.41%	27.16%	50.13%	59.27%			11.56%	40.9%	30.38%	1.99%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$19.70M	$26.15M	$0.00	$0.00	$1.752M	$1.696M	$1.268M	$1.637M	$2.220M	$549.0K	$796.0K	$487.0K	$127.0K
YoY Change	-24.66%			-100.0%	3.3%	33.75%	-22.54%	-26.26%	304.37%	-31.03%	63.45%	283.46%
% of Operating Profit
Other Income/Expense, Net	$29.58M	$26.67M	$4.843M	-$45.30M	$2.578M	$494.0K	-$827.0K	-$1.499M	-$2.210M	-$979.0K	-$3.219M	-$682.0K	-$134.0K
YoY Change	10.94%	450.59%	-110.69%	-1857.25%	421.86%	-159.73%	-44.83%	-32.17%	125.74%	-69.59%	371.99%	408.96%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$160.9M	-$281.7M	-$212.2M	-$173.4M	-$98.15M	-$66.60M	-$42.95M	-$33.46M	-$29.99M	-$25.88M	-$20.89M	-$14.24M	-$13.43M
YoY Change	-42.88%	32.79%	22.35%	76.66%	47.37%	55.06%	28.36%	11.57%	15.88%	23.89%	46.7%	6.03%
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00			$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$160.9M	-$281.7M	-$212.2M	-$173.4M	-$98.15M	-$66.60M	-$42.95M	-$33.46M	-$29.99M	-$25.88M	-$20.89M	-$14.24M	-$13.43M
YoY Change	-42.88%	32.79%	22.36%	76.66%	47.38%	55.05%	28.36%	11.57%	15.88%	23.88%	46.74%	6.05%	-17.23%
Net Earnings / Revenue	-253.3%	-292.55%	-379.89%	-551.59%	-919.0%	-1405.02%	-1046.08%	-760.15%	-1233.73%		-2151.8%	-533.3%	-1147.61%
Basic Earnings Per Share	-$1.64	-$2.91	-$2.24	-$2.10
Diluted Earnings Per Share	-$1.64	-$2.91	-$2.239M	-$2.105M	-$1.439M	-$1.185M	-$1.023M	-$1.054M	-$1.177M	-$1.266M	-$1.090M	-$743.2K	-$700.9K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$315.2M	$436.2M	$615.9M	$482.9M	$221.4M	$201.0M	$100.9M	$92.10M	$64.80M	$49.10M	$54.00M	$9.100M	$6.400M
YoY Change	-27.75%	-29.17%	27.54%	118.11%	10.15%	99.21%	9.55%	42.13%	31.98%	-9.07%	493.41%	42.19%
Cash & Equivalents	$41.87M	$61.33M	$133.6M	$167.3M	$99.80M	$190.5M	$89.00M	$88.60M	$64.80M	$49.10M	$54.00M	$9.100M	$6.400M
Short-Term Investments	$273.3M	$374.9M	$482.3M	$315.6M	$121.6M	$10.50M	$12.00M	$3.500M
Other Short-Term Assets	$14.54M	$27.37M	$8.826M	$5.900M	$5.700M	$3.700M	$1.600M	$1.200M	$800.0K	$800.0K	$600.0K	$700.0K	$300.0K
YoY Change	-46.87%	210.07%	49.59%	3.51%	54.05%	131.25%	33.33%	50.0%	0.0%	33.33%	-14.29%	133.33%
Inventory
Prepaid Expenses
Receivables	$1.826M	$38.48M	$8.676M	$5.500M	$0.00	$500.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$331.5M	$502.1M	$633.4M	$494.3M	$227.1M	$205.2M	$102.6M	$93.30M	$65.70M	$49.90M	$54.70M	$9.800M	$6.700M
YoY Change	-33.97%	-20.74%	28.14%	117.66%	10.67%	100.0%	9.97%	42.01%	31.66%	-8.78%	458.16%	46.27%
Property, Plant & Equipment	$158.5M	$176.1M	$162.2M	$99.40M	$34.20M	$5.100M	$2.600M	$1.600M	$2.200M	$1.200M	$800.0K	$1.200M	$1.000M
YoY Change	-9.98%	8.53%	63.23%	190.64%	570.59%	96.15%	62.5%	-27.27%	83.33%	50.0%	-33.33%	20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$980.0K	$4.942M	$100.7M		$39.40M
YoY Change	-80.17%	-95.09%
Other Assets	$15.19M	$15.26M	$15.26M	$15.20M	$200.0K	$800.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K
YoY Change	-0.48%	0.0%	0.39%	7500.0%	-75.0%	700.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Total Long-Term Assets	$174.7M	$203.5M	$288.0M	$128.2M	$75.20M	$7.800M	$2.700M	$1.700M	$2.300M	$1.300M	$900.0K	$1.300M	$1.200M
YoY Change	-14.16%	-29.36%	124.68%	70.48%	864.1%	188.89%	58.82%	-26.09%	76.92%	44.44%	-30.77%	8.33%
Total Assets	$506.2M	$705.6M	$921.5M	$622.5M	$302.3M	$213.0M	$105.3M	$95.00M	$68.00M	$51.20M	$55.60M	$11.10M	$7.900M
YoY Change
Accounts Payable	$4.719M	$8.265M	$8.612M	$6.300M	$5.800M	$4.200M	$1.700M	$900.0K	$1.000M	$600.0K	$700.0K	$2.300M	$1.900M
YoY Change	-42.9%	-4.03%	36.7%	8.62%	38.1%	147.06%	88.89%	-10.0%	66.67%	-14.29%	-69.57%	21.05%
Accrued Expenses	$33.69M	$59.56M	$47.99M	$18.90M	$16.40M	$10.90M	$7.300M	$4.000M	$2.400M	$2.300M	$2.000M
YoY Change	-43.44%	24.11%	153.91%	15.24%	50.46%	49.32%	82.5%	66.67%	4.35%	15.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$1.000M
YoY Change												-100.0%
Long-Term Debt Due					$0.00	$2.400M	$0.00	$8.200M	$7.600M	$1.500M	$1.700M	$1.900M	$200.0K
YoY Change					-100.0%		-100.0%	7.89%	406.67%	-11.76%	-10.53%	850.0%
Total Short-Term Liabilities	$39.09M	$114.1M	$81.28M	$85.60M	$27.80M	$27.30M	$11.00M	$15.20M	$13.40M	$4.600M	$4.600M	$4.900M	$3.700M
YoY Change	-65.72%	40.31%	-5.04%	207.91%	1.83%	148.18%	-27.63%	13.43%	191.3%	0.0%	-6.12%	32.43%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$12.40M	$14.80M	$2.500M	$10.70M	$18.10M	$0.00	$1.700M	$3.600M
YoY Change					-100.0%	-16.22%	492.0%	-76.64%	-40.88%		-100.0%	-52.78%
Other Long-Term Liabilities	$98.71M	$107.6M	$161.3M	$152.4M	$29.70M	$12.90M	$2.200M	$4.200M	$5.800M	$200.0K	$100.0K	$800.0K	$1.000M
YoY Change	-8.24%	-33.32%	5.86%	413.13%	130.23%	486.36%	-47.62%	-27.59%	2800.0%	100.0%	-87.5%	-20.0%
Total Long-Term Liabilities	$98.71M	$107.6M	$161.3M	$152.4M	$29.70M	$25.30M	$17.00M	$6.700M	$16.50M	$18.30M	$100.0K	$2.500M	$4.600M
YoY Change	-8.24%	-33.32%	5.86%	413.13%	17.39%	48.82%	153.73%	-59.39%	-9.84%	18200.0%	-96.0%	-45.65%
Total Liabilities	$137.8M	$221.6M	$242.6M	$238.0M	$57.50M	$52.60M	$28.10M	$21.90M	$29.90M	$22.80M	$4.700M	$7.400M	$8.200M
YoY Change	-37.82%	-8.65%	1.94%	313.91%	9.32%	87.19%	28.31%	-26.76%	31.14%	385.11%	-36.49%	-9.76%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	98.41M	96.83M	94.75M	82.39M
Diluted Shares Outstanding	98.41M	96.83M	94.75M	82.39M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $291.57 Million

About FATE THERAPEUTICS INC

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 181 full-time employees. The company went IPO on 2013-10-01. The firm is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.

Industry: Biological Products, (No Diagnostic Substances) Peers: BIOCRYST PHARMACEUTICALS INC EQRx, Inc. ImmunityBio, Inc. Prometheus Biosciences, Inc. Relay Therapeutics, Inc. Sage Therapeutics, Inc. PROKIDNEY CORP. Twist Bioscience Corp Verve Therapeutics, Inc.